IL17A and psoriasis: Drugs that inhibit TNFa, IL‐17A and IL‐23 have shown the greatest clinical effectiveness in the treatment of patients with psoriasis, but the systemic immunosuppressive effect, the need for regular administration and the high cost limit their use.